#Canada #Aurora Cannabis #Edmonton #Curaleaf Holdings #Takeover Bid

Aurora Cannabis Inc. Advises Shareholders to Delay Decisions

Aurora Cannabis Inc., a prominent fixture in the global medical cannabis sector, has issued a statement urging its shareholders to beware of making any short-term decisions in reaction to the unsolicited takeover bid from Curaleaf Holdings, Inc. This unsolicited offer has raised concerns, with Aurora's leadership emphasizing the need for a cautious approach.

Curaleaf's takeover bid is perceived as an attempt to pressure Aurora's shareholders into a quick decision that might benefit Curaleaf at the expense of Aurora’s long-term value. According to Aurora, Curaleaf aims to acquire its highly-rated EU-GMP facilities and established medical cannabis platform at a discounted price, which could deny Aurora shareholders significant future value.

Current Situation

On August 19, 2026, Aurora's Executive Chairman and CEO, Miguel Martin, publicly addressed the situation, stating, "The strong shareholder support showed during our 2026 AGM reiterates our commitment to the long-term strategy we are executing. We believe Curaleaf's offer is strategically designed to pressure our shareholders instead of being advantageous to them." Martin firmly reassured shareholders that the company is focused on sustainable growth, resisting any hurried decisions merely to appease Curaleaf.

Curaleaf's offer for Aurora consists of a combination of subordinate voting shares and cash, yet it is characterized by a cap that limits the value of Aurora Shares below their recent trading prices. This misalignment in valuation further exacerbates the concerns surrounding the potential acquisition.

Engagement with Curaleaf

Contrary to Curaleaf's claims, Aurora stated that recent communications indicate an ongoing dialogue between both companies, dating back to June 2026, only intensifying as late as August 12. This assertion further suggests that Curaleaf’s aggressive takeover tactics may not genuinely reflect an interest in collaboration, but rather a tactical play to secure Aurora's valuable assets at the lowest cost.

Advisory Measures

In light of this hostile takeover, Aurora has established a special committee of independent directors tasked with evaluating Curaleaf’s offer. The company advises its shareholders to refrain from taking any action until the board of directors can provide a formal recommendation, expected within the next 15 days. This recommendation will be disseminated through official news releases in accordance with securities laws.

Call to Action for Shareholders

Aurora encourages its shareholders to be informed and cautious. For inquiries regarding the takeover bid, Aurora has directed shareholders to reach out to Kingsdale Advisors, who will act as the strategic advisor and information agent for the company. This measure intends to ensure that shareholders remain abreast of developments and can make informed decisions based on Aurora’s official stance.

The Bigger Picture

As a leading global medical cannabis firm, Aurora is dedicated to providing high-quality products to its vast customer base spanning Canada, Europe, Australia, and New Zealand. With established brands and world-class manufacturing facilities, Aurora's long-term commitment to improving patient care is evident. They emphasize their intent to focus on strategic growth, rather than engaging in short-term actions that could undermine future potential.

In conclusion, with the backdrop of Curaleaf's unsolicited takeover bid, Aurora Cannabis Inc. is urging shareholders to hold their positions and await further guidance from the board. This move symbolizes Aurora’s commitment to safeguarding the interests of its shareholders while navigating the complexities of the cannabis industry’s evolving landscape.